(Q38097327)

28 August 2017

TNF inhibition for ophthalmic indications: current status and outlook (English)

1 reference

28 August 2017

0 references

Lana M Rifkin

1

1 reference

28 August 2017

Andrea D Birnbaum

series ordinal

2

1 reference

28 August 2017

Debra A Goldstein

series ordinal

3

1 reference

28 August 2017

language of work or name

1 reference

1 August 2013

1 reference

28 August 2017

1 reference

28 August 2017

27

1 reference

28 August 2017

4

1 reference

28 August 2017

347-357

1 reference

https://scigraph.springernature.com/pub.10.1007/s40259-013-0022-9

28 August 2017

0 references

cites work

Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0022-9

Incidence and prevalence of uveitis in Northern California; the Northern California Epidemiology of Uveitis Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0022-9

Federal Budgetary Costs of Blindness

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0022-9

The natural history of uveitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0022-9

Etiologies of chronic anterior uveitis at a tertiary referral center over 35 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0022-9

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0022-9

Evaluation of patients with scleritis for systemic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0022-9

Severity of scleritis and episcleritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0022-9

Biological functions of tumor necrosis factor cytokines and their receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0022-9

Risk factors for loss of visual acuity among patients with uveitis associated with juvenile idiopathic arthritis: the Systemic Immunosuppressive Therapy for Eye Diseases Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0022-9

21 January 2018

Etanercept in arthritis

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0022-9

Clinical pharmacokinetics of TNF antagonists: how do they differ?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0022-9

Infliximab and adalimumab for uveitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0022-9

A PEGylated Fab' fragment against tumor necrosis factor for the treatment of Crohn disease: exploring a new mechanism of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0022-9

Characterization of golimumab, a human monoclonal antibody specific for human tumor necrosis factor α.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0022-9

A single infliximab infusion vs corticosteroids for acute panuveitis attacks in Behçet's disease: a comparative 4-week study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0022-9

Infections in the immunocompromised rheumatologic patient

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0022-9

Overview of safety of non-biologic and biologic DMARDs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0022-9

Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0022-9

Inflammatory neurological disease in patients treated with tumor necrosis factor alpha inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0022-9

Optic neuritis associated with adalimumab in the treatment of uveitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0022-9

Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failu

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0022-9

A prospective trial of infliximab therapy for refractory uveitis: preliminary safety and efficacy outcomes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0022-9

Treatment of refractory posterior uveitis with infliximab: a 7-year follow-up study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0022-9

Infliximab effects compared to conventional therapy in the management of retinal vasculitis in Behçet disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0022-9

Comparison of infliximab versus ciclosporin during the initial 6-month treatment period in Behçet disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0022-9

Infliximab to treat chronic noninfectious uveitis in children: retrospective case series with long-term follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0022-9

Loss of efficacy during long-term infliximab therapy for sight-threatening childhood uveitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0022-9

Favourable effect of TNF-alpha inhibitor (infliximab) on Blau syndrome in monozygotic twins with a de novo CARD15 mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0022-9

Treatment of pediatric vogt-koyanagi-harada syndrome with infliximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0022-9

Tumor necrosis factor alpha blockade with infliximab for refractory uveitis and scleritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0022-9

Infliximab for the treatment of active scleritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0022-9

Infliximab for the treatment of refractory scleritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0022-9

Treatment of refractory uveitis with adalimumab: a prospective multicenter study of 131 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0022-9

Adalimumab therapy for refractory uveitis: results of a multicentre, open-label, prospective trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0022-9

Switching biologic agents for uveitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0022-9

Adalimumab in juvenile idiopathic arthritis-associated chronic anterior uveitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0022-9

Prevention of flare recurrences in childhood-refractory chronic uveitis: an open-label comparative study of adalimumab versus infliximab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0022-9

Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0022-9

Etanercept therapy in children with treatment-resistant uveitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0022-9

Efficacy of Etanercept in Preventing Relapse of Uveitis Controlled by Methotrexate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0022-9

Scleritis: a paradoxical effect of etanercept? Etanercept-associated inflammatory eye disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0022-9

Intravitreal infliximab for the treatment of sight-threatening chronic noninfectious uveitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0022-9

Adverse events after intravitreal infliximab (Remicade).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0022-9

Intravitreal adalimumab for refractory uveitis-related macular edema.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0022-9

10.1007/S40259-013-0022-9

21 January 2018

Identifiers

DOI

1 reference

release_hkn5rpjqzngblbly3itaqeyrby

28 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/hkn5rpjqzngblbly3itaqeyrby

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference